Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index
Author:
Affiliation:
1. Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel
2. Hebrew University, The Faculty of Medicine, Jerusalem, Israel
3. Department of Oncology, Sharett Institute, Hadassah Medical Center, Jerusalem, Israel
Abstract
Funder
Israel Cancer Association
Publisher
The Endocrine Society
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism
Link
http://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgaa458/33565382/dgaa458.pdf
Reference42 articles.
1. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med.,2015
2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med.,2015
3. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med.,2017
4. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med.,2015
5. Pembrolizumab as second-line therapy for advanced Urothelial carcinoma;Bellmunt;N Engl J Med.,2017
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Immunotherapy-Related Hypothyroidism: Mechanisms and Management;Hypothyroidism - Causes, Screening and Therapeutic Approaches [Working Title];2024-05-28
2. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study;European Journal of Cancer;2024-05
3. Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer;Heliyon;2024-03
4. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors;BMC Immunology;2024-01-24
5. Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events;Endocrine Journal;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3